Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Extension Study to Evaluate the Safety and Tolerability of Atrasentan

NCT00127478 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00127478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00127478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Extension Study to Evaluate the Safety and Tolerability of Atrasentan
Lead sponsor
Abbott
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2001
Completion date
June 30, 2007
Enrollment
166 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, prostate cancer